(Q26766699)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alberto Q. Farias

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Tiago Seva-Pereira

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Edison Roberto Parise

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Paulo Lisboa Bittencourt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Eduardo Luiz Rachid Cançado

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Cynthia Levy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Gilda Porta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Antônio Eduardo Benedito Silva

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Debora Raquel Benedita Terrabuio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Roberto José de Carvalho Filho

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Dalton Marques Chaves

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Irene Kazue Miura

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Liana Codes

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Luciana Costa Faria

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Andreia Silva Evangelista

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Luciana Lofêgo Gonçalves

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Michele Harriz

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Edmundo Pessoa A Lopes Neto

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Gustavo Oliveira Luz

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Patrícia Oliveira

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Elze Maria Gomes de Oliveira

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Janaina Luz Narciso Schiavon

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Brazilian Society of Hepatology on the Diagnosis and Management of Autoimmune Diseases of the Liver

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

Arquivos de Gastroenterologia

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

52 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

15-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26959804%20AND%20SRC:MED&resulttype=core&format=json

Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Acute and acute severe (fulminant) autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Classification of smooth muscle autoantibodies detected by immunofluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Human SepSecS or SLA/LP: selenocysteine formation and autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoantibodies as prognostic markers in autoimmune liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoantibodies in autoimmune hepatitis: anti-liver kidney microsome type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Clinical significance of autoantibodies in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Simplified criteria for the diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Performance parameters of the diagnostic scoring systems for autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune acute liver failure: proposed clinical and histological criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Chloroquine for the maintenance of remission of autoimmune hepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Management and outcome of pregnancy in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Treatment of autoimmune hepatitis: a review of current and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Advances in the current treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune hepatitis: focusing on treatments other than steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pharmacological management of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Successful treatment of refractory autoimmune hepatitis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Review article: the management of autoimmune hepatitis beyond consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

An update on primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Genetic epidemiology of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune pancreatitis and IgG4-associated sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

IgG4-related sclerosing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Sclerosing cholangitis: a focus on secondary causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Bezafibrate for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pregnancy in primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary sclerosing cholangitis and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Risk factors for complications of ERCP in primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Four years experience with short term stenting in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Diagnostic and therapeutic challenges in pediatric primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Sclerosing cholangitis: pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Unique features of primary sclerosing cholangitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Current management of primary sclerosing cholangitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Specificities of sclerosing cholangitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Clinical significance of autoantibodies in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoantibodies in primary biliary cirrhosis: antimitochondrial autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Serum reactivity against bacterial pyruvate dehydrogenase: increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Antinuclear antibodies as ancillary markers in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis: a 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Diagnosis and management of the overlap syndromes of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis: overlaps with other autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis: therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Fibrate for treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Fenofibrate treatment in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Long-term fibrate treatment for PBC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pruritus in cholestasis: facts and fiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Advances in pathogenesis and management of pruritus in cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The 5-D itch scale: a new measure of pruritus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Update on primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The true impact of fatigue in primary biliary cirrhosis: a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Quality of life in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Management of osteoporosis in liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Bone mineral density before and after OLT: long-term follow-up and predictive factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

AGA technical review on osteoporosis in hepatic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Infection after ERCP, and antibiotic prophylaxis: a sequential quality-improvement approach over 11 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary sclerosing cholangitis: a review and update on therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Antibiotics for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Resection of Hepatic Duct Bifurcation and Transhepatic Stenting for Sclerosing Cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Primary sclerosing cholangitis: role of extrahepatic biliary resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Current consensus on the management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Cancer surveillance in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune liver disease, autoimmunity and liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Acute autoimmune hepatitis: many open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Autoimmune hepatitis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Model for end-stage liver disease (MELD) exception for bacterial cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the s

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Increased incidence of hypothyroidism in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

1 reference

7 January 2021

Pathophysiology and current management of pruritus in liver disease.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Antibiotic prophylaxis for GI endoscopy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Gallbladder disease in patients with primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

High lifetime risk of cancer in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

1 reference

7 January 2021

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Antibiotic prophylaxis for gastrointestinal endoscopy. American Society for Gastrointestinal Endoscopy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Elevated levels of bile acids in colostrum of patients with cholestasis of pregnancy are decreased following ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Small-duct primary sclerosing cholangitis: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a Working Party for the British Society of Gastroenterology Endoscopy Committee

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Primary sclerosing cholangitis: resect, dilate, or transplant?

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Ibandronate and Calcitriol Reduces Fracture Risk, Reverses Bone Loss, and Normalizes Bone Turnover After lTX

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Is there a role for liver biopsy in primary sclerosing cholangitis?

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Pregnancy in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

The role of autoantibodies as diagnostic markers of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

[Autoimmune hepatitis]

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Autoimmune liver diseases

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Fenofibrate for patients with asymptomatic primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021

Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032015000500002

7 January 2021